Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: A phase II Southwest Oncology Group study (S9504)

Clinical Lung Cancer

Volumn 8, Issue 2, 2006, Pages 116-121

  Gandara, David R ^a,b   Chansky, Kari ^c   Albain, Kathy S ^d   Gaspar, Laurie E ^e   Lara Jr , Primo N ^a,b   Kelly, Karen ^e   Crowley, John ^c   Livingston, Robert ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^c SW Oncol Group Statistical Center   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cisplatin; Esophagitis; Etoposide; Pneumonitis

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERABILITY; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LONG TERM CARE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; RADIATION DOSE; RADIATION PNEUMONIA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES;

EID: 33750188024     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2006.n.039     Document Type: Article

References (29)

1. Goldberg Z, Gaspar LE, Lira P, et al. Combined modality treatment of non-small cell lung cancer. In: Pass H, ed. Lung Cancer: Principles and Practice. New York, NY: Lippincott Williams & Wilkins; 2001:1-11.
2. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:2692-2699.
3. Curran W, Scott C, Langer R, et al. Phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III non-small cell lung cancer (NSCLC): report of Radiation Therapy Oncology Group (RTOG) 9410. Lung Cancer 2000; 29:93 (Abstract #303).
4. Fournel, P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: Groupe Lyon-Saint Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 study. J Clin Oncol 2005; 23:5910-5917.
5. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small cell lung cancer: a phase II Southwest Oncology Group study (S9504). J Clin Oncol 2003; 21:2004-2010.
6. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992; 326:524-530.
7. Gandara DR, Vokes E, Green M, et al. Activity of docetaxel in platinum-treated non-small cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 2000; 18:131-135.
8. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell long cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-2103.
9. Albain KS, Crowley JJ, Turrisi AT, et al. Concurrent cisplatin, etoposide plus radiotherapy for pathologic stage IIIB non-small cell lung cancer: a Southwest Oncology Group phase II study (S9019). J Clin Oncol 2002; 20:3454-3460.
10. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: mature results of SWOG 8805. J Clin Oncol 1995; 13:1880-1892.
11. Kaplan E, Meier P. Nonparametric estimation form incomplete observations. J Am Stat Assoc 1958; 53:457-481.
12. Vokes E. Optimal therapy for unresectable stage III non-small cell lung cancer. J Clin Oncol 2005; 23:5853-5855.
13. Rosenman JG, Socinski MA. Does more aggressive therapy improve outcomes in the treatment of unresectable stage III non-small cell lung cancer? Semin Oncol 2005; 32(2 suppl 3):S13-S17.
14. Gandara DR, Vallieres E, Gaspar LE, et al. Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy. Clin Lung Cancer 2005; 7(suppl 3):S93-S97.
15. Socinski MA, Morris DE, Halle JS, et al. Induction and concurrent chemotherapy with high-dose conformal thoracic radiation therapy in unresectable stage IIIA and IIIB non-small cell lung cancer: a dose-escalation phase I trial. J Clin Oncol 2004; 22:43-50.
16. Blackstock AW, Socinski MA, Gu L, et al. Initial pulmonary toxicity evaluation of chemoradiotherapy (CRT) utilizing 74 Gy 3-dimensional (3-D) thoracic radiation in stage III non-small cell lung cancer (NSCLC): a Cancer and Leukemia Group B (CALGB) randomized phase II trial. J Clin Oncol 2005; 23(16 suppl):634a (Abstract #7060).
17. Belani CP, Wang W, Johnson DH, et al. Phase III study of the Eastern Cooperative Ontology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 2005; 23:3760-3767.
18. Belani CP, Aisner J, Day R, et al. Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy for locally advanced non-small cell lung cancer: three year follow-up. Proc Am Soc Clin Oncol 1997; 16:448a (Abstract #1608)
19. Choy H, Akerley W, Safran H, et al. Multiinstitutional phase II trial of paclitaxel, carboplatin and concurrent radiation therapy for locally advanced inoperable non-small cell lung cancer. J Clin Oncol 1998; 16:3316-3322.
20. Lau D, Leigh B, Gandara D, et al. Twice weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/ paclitaxel consolidation for stage III non-small cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol 2001; 19:442-447.
21. Vokes EE, Herndon JE II, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB NSCLC: Cancer and Leukemia Group B study 9431. J Clin Oncol 2002; 20:4191-4198.
22. Vokes EE, Herndon JE, Kelley MJ, et al. Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): initial analysis of a randomized phase III trial. Proc Am Soc Clin Oncol 2004; 23:616 (Abstract #7005).
23. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol (LAMP). J Clin Oncol 2005; 23:5883-5891.
24. Gandara DR, Narayan S, Lara PN, et al. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res 2005; 11(13 suppl):5057s-5062s.
25. Henderson IC, Berry D, Demetri G, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast. J Clin Oncol 2003; 21:976-983.
26. Kelly K, Gaspar LE, Chansky K, et al. Low incidence of pneumonitis on SWOG 0023: a preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and gefitinib/placebo maintenance in patients with inoperable stage III non-small cell lung cancer (with late breaking survival update). J Clin Oncol 2005; 23(16 suppl):634s (Abstract #7058).
27. Gaspar LE, Chansky K, Albain KS, et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol 2005; 23:2955-2961.
28. Sekine I, Nokihara H, Sumi M, et al. Docetaxel (D) consolidation therapy following cisplatin (P), vinorelbine (V) and concurrent thoracic radiotherapy (TRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC). J Clin Oncol 2005; 23(16 suppl):651s (Abstract #7125).
29. Kelly K, Gaspar L, Chansky K, et al. A randomized phase III trial of cisplatin/etoposide + concurrent radiotherapy followed by consolidation docetaxel, then maintenance therapy with gefitinib or placebo in patients with inoperable stage III NSCLC: preliminary results of S0023. Presented at: International Association for the Study of Lung Cancer 11th World Conference on Lung Cancer; July 3-6, 2005; Barcelona, Spain. Abstract #O192-a.